Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Early Clinical Trials Show That Novel Experimental Drug Shrinks Tumors in Patients with Various Types of Cancer

02.06.2003


As more is learned about how cancer develops, scientists have begun designing new drugs that directly target cancer cells, leaving healthy ones intact. Having fewer side effects, some of these drugs work by blocking growth signaling processes within cancer cells, while others enlist the body’s immune system to recognize and mount an attack against the cancer cell. But regardless of how they work, most of these drugs are designed to treat a specific cancer and cannot be used to treat other tumor types.

Now, an early clinical trial at the Cedars-Sinai Medical Center has shown that an experimental drug called 2C4 (trade name is Omnitarg) was effective to shrink tumors in patients with several different types of cancer. The findings, presented at the 39th annual meeting of the American Society of Clinical Oncology in Chicago, may lead to a new way to treat various types of cancer.

"What’s interesting is that this drug effectively shrank tumors in several completely different types of cancer in early stage clinical trials," said David Agus, M.D., Research Director at the Cedars-Sinai Prostate Cancer Center and first author of the study. "This tells us that the drug targets a growth signaling pathway in cancer cells that is common in many solid tumors."



The drug, called 2C4 and developed by Genentech, Inc., is a monoclonal antibody, or protein that enlists the body’s immune system to attack foreign invaders, such as viruses or bacteria. It works by targeting HER-2/neu, a member of the HER kinase family of proteins. The protein sits on the surface of cancer cells and receives signals from growth factor molecules within the HER family, which in, turn stimulate tumors to grow.

But earlier research in Dr. Agus’ laboratory indicated that 2C4 was not limited to targeting HER-2/neu alone and blocked signaling activity among the entire HER network of proteins in both breast and prostate cancer tumors grown in mice. These findings led the investigators to begin the first clinical trial to test the safety and effectiveness of the drug in patients with other types of solid-tumor cancers.

In the study, 21 patients with advanced cancers including breast, prostate, lung, ovarian, colon, pancreas and sarcoma received 2C4 by infusion every three weeks at a dose level ranging between 0.5 and 15 milligrams per kilogram of body weight. Among these patients, 19 completed at least two cycles or six weeks of treatment with 2C4, while two died at the outset of treatment due to complications of their disease. The investigators found that eight or 42 percent of the 19 patients treated with 2C4, responded to treatment either because their tumors shrank over 50 percent, or because their tumors stopped growing for a given time period before their disease progressed. (Cedars-Sinai IRB No. 3691)

Of the 19 patients who received 2C4, three achieved partial remission as measured by shrinkage of their tumors by over 50 percent. These included one patient with ovarian cancer, who received 5 mg/kg of 2C4; one with prostate cancer, who received 15 mg/kg of 2C4; and one patient with a pancreatic neuroendocrine cancer who received 15 mg/kg of 2C4. Two of these patients (ovarian and pancreatic cancer) remain in remission and have been receiving 2C4 for over a year since beginning therapy.

"To see results that show activity in a Phase I safety trial is remarkable, especially since these patients were in the advanced stages of their disease and had no other treatment options available to them," said Dr. Agus. "This is especially exciting as there was little drug related toxicity or side effects associated with this treatment." v In addition, the investigators report that five additional patients’ disease stabilized for at least three months after just two treatment cycles with 2C4. These patients included three with cancers of the prostate, one with non-small cell lung cancer and one with ovarian cancer.

"Targeting a pathway, rather than a tumor type, is an exciting new area in the treatment of cancer, and 2C4 is one of several experimental drugs that show how this treatment strategy can benefit patients," commented Dr. Agus.

A Phase II clinical trial with 2C4 started in May, 2003 at Cedars-Sinai Medical Center to evaluate the effectiveness of the drug in patients with advanced cancers of the prostate, (Cedars-Sinai IRB No. 4100-01) and is scheduled to be open for ovarian cancer patients in June.

Cedars-Sinai Medical Center is one of the largest non-profit academic medical centers in the Western United States. For the fifth straight two-year period, Cedars-Sinai has been named Southern California’s gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. Named one of the 100 "Most Wired" hospitals in health care in 2001, the Medical Center ranks among the top 10 non-university hospitals in the nation for its research activities.

Kelli Stauning | Cedars-Sinai Medical Center

More articles from Health and Medicine:

nachricht Diabetes mellitus: A risk factor for early colorectal cancer
27.05.2020 | Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

nachricht Ultra-thin fibres designed to protect nerves after brain surgery
27.05.2020 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Biotechnology: Triggered by light, a novel way to switch on an enzyme

In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".

Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...

Im Focus: New double-contrast technique picks up small tumors on MRI

Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.

researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...

Im Focus: I-call - When microimplants communicate with each other / Innovation driver digitization - "Smart Health“

Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.

When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...

Im Focus: When predictions of theoretical chemists become reality

Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.

Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...

Im Focus: Rolling into the deep

Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.

A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

German-British Research project for even more climate protection in the rail industry

28.05.2020 | Transportation and Logistics

A special elemental magic

28.05.2020 | Physics and Astronomy

Skoltech scientists get a sneak peek of a key process in battery 'life'

28.05.2020 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>